Wednesday February 10 2010 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
  • A-Z

BioNews - BioPortfolio's News Portal
New Drug Applications IND Headlines

Sign-up to BioPortfolio's
New Drug Application IND news alerts.
Subscribe to BioWatch News Email alerts - open BioWatch PDF brochure.
Publish your news using BioNewsCast - open BioNewsCast PDF brochure.

Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
Pharma Live:  similar ...
The eCTD Upgrade: Cross-Application Linking
Pharmaceutical Technology:  similar ...
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
Genetic Engineering News:  similar ...
TOPICA Pharmaceuticals' IND application accepted for the use of luliconazole
News-Medical.Net:  similar ...
FDA Accepts TOPICA'S Luliconazole IND To Begin Clinical Trials In Onychomycosis
Medical News Today:  similar ...
TOPICA's IND for onychomycosis antifungal agent accepted by FDA
News-Medical.Net:  similar ...
TOPICA's IND for onychomycosis antifungal agent accepted by FDA
News-Medical.Net:  similar ...
Repros New IND for the Investigation of Androxal in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism ..
PR inside:  similar ...
FDA Accepts TOPICA'S Luliconazole IND to Begin Clinical Trials in Onychomycosis
Pharmacy Choice:  similar ...
Omeros Announces National Institute On Drug Abuse's Support For Phase 2 Clinical Study In Addiction Program
Medical News Today:  similar ...
Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
Genetic Engineering News:  similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
Genetic Engineering News:  similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
Forbes.com:  similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
Street Insider:  similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
RBC Dain Rauscher:  similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
Yahoo! Canada:  similar ...
ACT BIOTECH Announces FDA Acceptance of IND for ACTB1003, a First-in-Class Anti-Cancer Therapeutic
NewsBlaze:  similar ...
BDSI to discuss planned BEMA Granisetron IND with the FDA
News-Medical.Net:  similar ...
Biocon files IND for IN105 oral insulin with USFDA
Moneycontrol.com:  similar ...
Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers' Diarrhea
Pharmacy Choice:  similar ...

Search BioNews

      ---Advanced searching---

Sign-up to BioPortfolio's New Drug Application IND news alerts.
Subscribe to BioWatch News Email alerts - open BioWatch PDF brochure.
Publish your news using BioNewsCast - open BioNewsCast PDF brochure.

 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright © 1997-2009 - BioPortfolio Limited.